Aquestive Therapeutics Future Growth
Future criteria checks 2/6
Aquestive Therapeutics is forecast to grow earnings and revenue by 50.3% and 28.9% per annum respectively while EPS is expected to grow by 52.8% per annum.
Key information
50.3%
Earnings growth rate
52.8%
EPS growth rate
Pharmaceuticals earnings growth | 27.6% |
Revenue growth rate | 28.9% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 05 Jun 2024 |
Recent future growth updates
Recent updates
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
May 22Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Apr 09Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 28Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
Jan 19Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing
Jan 05Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement
Apr 17Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction
Oct 11Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film
Sep 28Aquestive Therapeutics: FDA Stymies Libervant Launch
Sep 05Aquestive Therapeutics: A First Take
Aug 29Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 78 | -17 | -20 | -16 | 5 |
12/31/2025 | 59 | -38 | -31 | -29 | 8 |
12/31/2024 | 50 | -45 | -20 | -31 | 9 |
3/31/2024 | 52 | -29 | -27 | -26 | N/A |
12/31/2023 | 51 | -8 | -7 | -6 | N/A |
9/30/2023 | 48 | -12 | 6 | 7 | N/A |
6/30/2023 | 47 | -23 | 10 | 12 | N/A |
3/31/2023 | 47 | -33 | 11 | 13 | N/A |
12/31/2022 | 48 | -54 | -12 | -10 | N/A |
9/30/2022 | 48 | -71 | -29 | -26 | N/A |
6/30/2022 | 50 | -73 | -40 | -38 | N/A |
3/31/2022 | 52 | -69 | -34 | -33 | N/A |
12/31/2021 | 51 | -71 | -34 | -33 | N/A |
9/30/2021 | 47 | -62 | -39 | -38 | N/A |
6/30/2021 | 42 | -64 | -38 | -38 | N/A |
3/31/2021 | 48 | -54 | -46 | -46 | N/A |
12/31/2020 | 46 | -56 | -46 | -45 | N/A |
9/30/2020 | 55 | -48 | -43 | -43 | N/A |
6/30/2020 | 59 | -50 | -49 | -49 | N/A |
3/31/2020 | 49 | -68 | -57 | -56 | N/A |
12/31/2019 | 53 | -66 | -61 | -60 | N/A |
9/30/2019 | 53 | -68 | -54 | -52 | N/A |
6/30/2019 | 54 | -64 | -51 | -49 | N/A |
3/31/2019 | 57 | -80 | -33 | -31 | N/A |
12/31/2018 | 67 | -61 | -15 | -13 | N/A |
9/30/2018 | 63 | -61 | -19 | -18 | N/A |
6/30/2018 | 77 | -38 | 8 | 10 | N/A |
3/31/2018 | 74 | -8 | 1 | 3 | N/A |
12/31/2017 | 67 | -14 | N/A | 6 | N/A |
12/31/2016 | 52 | -12 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AQST is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AQST is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AQST is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AQST's revenue (28.9% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: AQST's revenue (28.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AQST's Return on Equity is forecast to be high in 3 years time